Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Vaxart, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Vaxart appointed Dr. James B. Breitmeyer to its Board of Directors on April 23, 2026, bringing external expertise from biotech leadership roles. This board expansion strengthens governance and oversight capabilities with an independent director who has relevant industry experience.
Key Takeaways
Dr. Breitmeyer is an independent director meeting Board independence standards, reducing potential conflicts of interest
His dual roles as CEO of Altay Therapeutics and Operating Partner at SOLVE FSHD bring relevant biotech and therapeutic expertise to Vaxart's board
2 more takeaways